Bacci G, Dallari D, Battistini A, Orlandi M, Ferrari S, Avella M, Picci P, Casadei R, Ruggieri P
Sezione Chemioterapia dei Tumori Ossei, Istituto Ortopedico Rizzoli, Bologna.
Chir Organi Mov. 1992 Apr-Jun;77(2):171-80.
The values for serum alkaline phosphatase were evaluated in 340 patients affected with osteosarcoma of the limbs. The percentage of patients with high values for the enzyme at the onset of disease was significantly higher in the 69 cases who presented with metastases at the time of diagnosis, as compared to the 271 cases in which the neoplasm still appeared to be localized (81% vs 62%: p less than 0.001). In this last group of patients, treated with neoadjuvant chemotherapy, an evident relationship between values for alkaline phosphatase and prognosis was demonstrated. The percentage of patients who developed metastases was in fact 22% in the group with normal serum values for the enzyme at the onset of the disease and 40% for the patients with high values of the same (P less than 0.001). These data confirm the prognostic value for serum alkaline phosphatase in osteosarcoma, which should be taken into consideration when planning chemotherapy and in classifying patients for randomized therapeutic studies.
对340例肢体骨肉瘤患者的血清碱性磷酸酶值进行了评估。在诊断时出现转移的69例患者中，疾病初发时酶值高的患者百分比，显著高于肿瘤仍局限的271例患者（81% 对62%：p<0.001）。在最后一组接受新辅助化疗的患者中，碱性磷酸酶值与预后之间存在明显关联。事实上，疾病初发时酶血清值正常的患者组中发生转移的患者百分比为22%，而酶值高的患者组为40%（P<0.001）。这些数据证实了血清碱性磷酸酶在骨肉瘤中的预后价值，在规划化疗以及对患者进行随机治疗研究分类时应予以考虑。
